Clinical Study
Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases: A Single Institution Experience
Table 1
Patient characteristics of those treated with 90Y for liver-dominant metastatic colorectal cancer.
| | n (%) | Median | Range |
| | Age (years) | | 64 | 37–83 | | Male | 35 (68.6) | | | | Female | 16 (31.4) | | | | Time from diagnosis of metastases to 1st Rx (months) | | 23.2 | 1.3–99.9 | | Extrahepatic disease present | 28 (58.3) | | | | Pulmonary nodules present | 14 (28.5) | | | | Previous liver-directed therapy | 16 (31.4) | | | | Previous liver resection | 12 (23.5) | | | | Previous RFA | 11 (21.5) | | | | Previous hepatic artery chemoinfusion | 5 (9.8) | | | | Failed either bevacizumab or cetuximab* | 33 (73.3) | | | | Failed both bevacizumab or cetuximab | 9 (20.0) | | | | Failed capecitabine | 14 (31.1) | | |
|
|
*Those receiving both bevacizumab and cetuximab also included.
|
